Figure 8
In vivo malgrowth of Nrf1α−/− cells-derived subcutaneous tumour xenografts in nude mice.
Either HepG2 (Nrf1α+/+) or HEA157 (Nrf1α−/−) cells that had been growing in the exponential phase were inoculated subcutaneously into male nude mice, followed by observation of the subcutaneous tumour xenografts that had emerged and developed. (a) Shows that the tumour sizes were successively measured until six weeks when the mice were sacrificed before the transplanted tumors were excised. The results of growing tumour sizes were calculated as a fold change (mean ± S.D.) and then are shown graphically (n = 7 per group). (b) Shows that the in vitro cell proliferation determined by MTS assay (n = 9). Significant increase ($p < 0.05) in the proliferation of Nrf1α−/− cells and relevant exnograft tumourogenesis are indicated, relative to the control values obtained from Nrf1α+/+ cells. (c) Shows two groups of different subcutaneous tumour-bearing mice that were inoculated with either HepG2 (Nrf1α+/+) or HEA157 (Nrf1α−/−) cells. (d) Two groups of different xenograft tumors with different sizes were excised after the mice were sacrificed and were also subjected to the histopathological and other examinations (shown below).
